Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1971 1
1973 2
1976 2
1977 1
1978 4
1979 1
1980 1
1981 3
1982 5
1983 5
1985 4
1986 1
1988 2
1989 1
1990 2
1991 5
1992 4
1993 5
1994 2
1995 2
1996 2
1997 2
1998 2
1999 2
2000 1
2001 1
2002 3
2003 2
2005 1
2006 3
2007 1
2008 3
2009 1
2010 8
2011 3
2012 2
2013 3
2014 4
2015 6
2016 12
2017 9
2018 7
2019 6
2020 4
2021 5
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

139 results
Results by year
Filters applied: . Clear all
Page 1
Phase 2 Trial of Ibudilast in Progressive Multiple Sclerosis.
Fox RJ, Coffey CS, Conwit R, Cudkowicz ME, Gleason T, Goodman A, Klawiter EC, Matsuda K, McGovern M, Naismith RT, Ashokkumar A, Barnes J, Ecklund D, Klingner E, Koepp M, Long JD, Natarajan S, Thornell B, Yankey J, Bermel RA, Debbins JP, Huang X, Jagodnik P, Lowe MJ, Nakamura K, Narayanan S, Sakaie KE, Thoomukuntla B, Zhou X, Krieger S, Alvarez E, Apperson M, Bashir K, Cohen BA, Coyle PK, Delgado S, Dewitt LD, Flores A, Giesser BS, Goldman MD, Jubelt B, Lava N, Lynch SG, Moses H, Ontaneda D, Perumal JS, Racke M, Repovic P, Riley CS, Severson C, Shinnar S, Suski V, Weinstock-Guttman B, Yadav V, Zabeti A; NN102/SPRINT-MS Trial Investigators. Fox RJ, et al. Among authors: goldman md. N Engl J Med. 2018 Aug 30;379(9):846-855. doi: 10.1056/NEJMoa1803583. N Engl J Med. 2018. PMID: 30157388 Free PMC article. Clinical Trial.
Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension.
Kapoor R, Ho PR, Campbell N, Chang I, Deykin A, Forrestal F, Lucas N, Yu B, Arnold DL, Freedman MS, Goldman MD, Hartung HP, Havrdová EK, Jeffery D, Miller A, Sellebjerg F, Cadavid D, Mikol D, Steiner D; ASCEND investigators. Kapoor R, et al. Among authors: goldman md. Lancet Neurol. 2018 May;17(5):405-415. doi: 10.1016/S1474-4422(18)30069-3. Epub 2018 Mar 12. Lancet Neurol. 2018. PMID: 29545067 Clinical Trial.
Lung dysfunction in diabetes.
Goldman MD. Goldman MD. Diabetes Care. 2003 Jun;26(6):1915-8. doi: 10.2337/diacare.26.6.1915. Diabetes Care. 2003. PMID: 12766133 Review. No abstract available.
The MSOAC approach to developing performance outcomes to measure and monitor multiple sclerosis disability.
LaRocca NG, Hudson LD, Rudick R, Amtmann D, Balcer L, Benedict R, Bermel R, Chang I, Chiaravalloti ND, Chin P, Cohen JA, Cutter GR, Davis MD, DeLuca J, Feys P, Francis G, Goldman MD, Hartley E, Kapoor R, Lublin F, Lundstrom G, Matthews PM, Mayo N, Meibach R, Miller DM, Motl RW, Mowry EM, Naismith R, Neville J, Panagoulias J, Panzara M, Phillips G, Robbins A, Sidovar MF, Smith KE, Sperling B, Uitdehaag BM, Weaver J; Multiple Sclerosis Outcome Assessments Consortium (MSOAC). LaRocca NG, et al. Among authors: goldman md. Mult Scler. 2018 Oct;24(11):1469-1484. doi: 10.1177/1352458517723718. Epub 2017 Aug 11. Mult Scler. 2018. PMID: 28799444 Free PMC article. Review.
Consensus Curriculum for Fellowship Training in Multiple Sclerosis and Neuroimmunology.
Hua LH, Obeidat AZ, Amezcua L, Cohen JA, Costello K, Dunn J, Gelfand JM, Goldman MD, Hopkins S, Jeffery D, Krieger S, Newsome SD, Shah S, Sicotte NL, Yadav V, Longbrake EE. Hua LH, et al. Among authors: goldman md. Neurol Clin Pract. 2021 Aug;11(4):352-357. doi: 10.1212/CPJ.0000000000001040. Neurol Clin Pract. 2021. PMID: 34484933
Clinical application of forced oscillation.
Goldman MD. Goldman MD. Pulm Pharmacol Ther. 2001;14(5):341-50. doi: 10.1006/pupt.2001.0310. Pulm Pharmacol Ther. 2001. PMID: 11603948 Review.
139 results